Skip to Content

Join the 'Follicular Lymphoma' group to help and get support from people like you.

Follicular Lymphoma News

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study authors said their findings add to growing evidence that noninvasive, blood-based biopsies may help detect cancer earlier by tracking its evolution. They said this test may also significantly change how the disease is treated. "Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said study co-senior author Dr. Ash Alizadeh, an assistant professor of medicine/oncology. ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Diagnosis and Investigation, Burkitt Lymphoma, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white blood cell in which most types of non-Hodgkin lymphoma occur. One-third of 32 patients treated with the modified T-cells experienced a complete remission of their non-Hodgkin lymphoma. And those pretreated with more aggressive chemotherapy did even better, researchers report. "It's a fantastic step forward," said Susanna Greer, director of clinical research and immunology at the American Cancer Society. "It's been difficult to make a lot of progress in lymphoma, especially in non-Hodgkin lymphoma, ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Follicular Lymphoma, Cutaneous T-cell Lymphoma, Diagnosis and Investigation, Burkitt Lymphoma, Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Mycosis Fungoides, Peripheral T-cell Lymphoma

FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma

Posted 29 Feb 2016 by Drugs.com

South San Francisco, CA – February 26, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan (rituximab)-containing regimen, or whose follicular lymphoma returned after such treatment. Follicular lymphoma is the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (NHL) and accounts for approximately one in five cases of NHL. "People with follicular lymphoma whose disease returns or worsens despite treatment with a Rituxan-containing regimen need more options because the disease becomes more difficult to treat each time it comes back," said Sandra Horning, M.D., chief medical officer and head of Global Product D ... Read more

Related support groups: Follicular Lymphoma, Obinutuzumab, Gazyva

FDA Approves Zydelig (idelalisib) for CLL and Lymphoma

Posted 23 Jul 2014 by Drugs.com

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). Used in combination with Rituxan (rituximab), Zydelig is to be used in patients for whom Rituxan alone would be considered appropriate therapy due to other existing medical conditions (co-morbidities). Zydelig is the fifth new drug with breakthrough therapy designation to be approved by the FDA and the third drug with this designation approved to treat CLL. The FDA is also granting Zydelig accelerated approval to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), another type of non-Hodgkin lymphoma. Zydelig is intended to be used in patients who ... Read more

Related support groups: Leukemia, Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Follicular Lymphoma

Zydelig Approved for Three Types of Blood Cancer

Posted 23 Jul 2014 by Drugs.com

WEDNESDAY, July 23, 2014 – Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL), the FDA said Wednesday in a news release. The approval for the three forms of blood cancer covers instances when the cancer returns despite treatment with at least one other therapy, the agency said. The drug's label will include a boxed warning that the medication could cause liver toxicity, diarrhea, high blood sugar, elevated liver enzymes, high blood triglycerides [a blood fat] and inflammation of the colon (colitis). Other side effects noted during clinical testing included fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills and rash. Zydelig is marketed by Gilead Sciences, based in Foster City, ... Read more

Related support groups: Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Follicular Lymphoma

Study Finds Big Strides Made in Treating Leukemia, Lymphoma in Past Decade

Posted 24 Nov 2010 by Drugs.com

WEDNESDAY, Nov. 24 – Clinicians have made remarkable advances in treating blood cancers with bone marrow and blood stem cell transplants in recent years, significantly reducing the risk of treatment-related complications and death, a new study shows. Between the early 1990s and 2007, there was a 41 percent drop in the overall risk of death in an analysis of more than 2,500 patients treated at Fred Hutchinson Cancer Center in Seattle, a leader in the field of blood cancers and other malignancies. Researchers from the Fred Hutchinson Cancer Center, who conducted the study, also noted dramatic decreases in treatment complications such as infection and organ damage. The study was published in the Nov. 24 issue of the New England Journal of Medicine "We have made enormous strides in understanding this very complex procedure and have yielded quite spectacular results," said study senior ... Read more

Related support groups: Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Cutaneous T-cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukemia, Hodgkin's Lymphoma, Burkitt Lymphoma, Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Chronic Eosinophilic Leukemia, Acute Promyelocytic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Acute Myeloblastic Leukemia, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Meningeal Leukemia

Treatment With Rituxan May Reduce Recurrence of Follicular Lymphoma

Posted 21 May 2010 by Drugs.com

THURSDAY, May 20 – The final phase of a drug study finds that two years of treatment with rituximab (Rituxan) cuts in half the risk that follicular lymphoma patients who respond to chemotherapy will suffer a recurrence of the disease. "These findings provide hope for the way we manage this disease. Rituximab maintenance therapy is likely to become a new standard of care for these patients," study author Dr. Gilles Salles, a professor of medicine at the University of Lyon in France, said in a news release. Typically, he noted, patients often relapse within a few years of their initial treatment. The researchers reached their conclusions after randomly assigning patients with follicular lymphoma to two years of treatment with the drug (505 patients) or no treatment with the drug (513 patients). After a median of 25 months, 34 percent of those who didn't take the treatment had recurrence ... Read more

Related support groups: Rituxan, Rituximab, Follicular Lymphoma

Ask a Question

Further Information

Related Condition Support Groups

Non-Hodgkin's Lymphoma

Related Drug Support Groups

clarithromycin, Rituxan, rituximab, interferon alfa-2b, Intron A, obinutuzumab, Zydelig, idelalisib, Gazyva